IP Library Granted Patent US 6,884,774
Granted Patent B2
US 6,884,774 · App. 10/030,161 · Granted Apr 26, 2005

Cyclic hexapeptide derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,884,774
App. No.
10/030,161
Granted
Apr 26, 2005
Kind
B2
Abstract

This invention relates to new polypeptide compound represented by the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory activity on β-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystic carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.

Claims (107)

1. A polypeptide compound of the following general formula (I):

wherein

R 1 is hydrogen or acyl group,

R 2 is hydrogen or acyl group,

R 3 is lower alkyl which has one or more hydroxy or protected hydroxy,

R 4 is hydrogen or hydroxy,

R 5 is hydrogen, hydroxy, lower alkoxy or hydroxysulfonyloxy, and

R 6 is hydroxy or acyloxy,

or a salt thereof.

2. The compound of claim 1 , wherein

R 1 is hydrogen, lower alkoxycarbonyl, higher alkanoyl or benzoyl substituted with one or more suitable substituent(s),

R 2 is hydrogen,

R 3 is lower alkyl which has one or more hydroxy,

R 4 is hydrogen or hydroxy,

R 5 is hydroxy or hydroxysulfonyloxy and

R 6 is hydroxy.

3. The compound of claim 2 , wherein

R 1 is hydrogen, lower alkoxycarbonyl, higher alkanoyl or benzoyl substituted with one or more suitable substituent(s),

R 2 is hydrogen,

R 3 is lower alkyl which has two hydroxy,

R 4 is hydrogen or hydroxy;

R 5 is hydroxy or hydroxysulfonyloxy; and

R 6 is hydroxy.

4. The compound of claim 3 , wherein

R 1 is benzoyl substituted with a suitable substituent selected from the group consisting of

thiadiazolyl substituted with phenyl having phenyl substituted with morphlino having lower alkyl,

thiadiazolyl substituted with phenyl having a suitable substituent selected from the group consisting of lower alkoxy(lower)alkoxy and lower alkoxy(higher)alkoxy,

piperazinyl substituted with phenyl having piperidyl substituted with a suitable substituent selected from the group consisting of phenyl having lower alkoxy(lower)alkoxy,

cyclo(lower)alkyloxy and lower alkoxy(lower)alkylthio,

piperazinyl substituted with phenyl having phenyl substituted with morpholino having lower alkyl,

imidazothiadiazolyl substituted with phenyl having piperidyl substituted with a suitable substituent selected from the group consisting of lower alkoxy(lower)alkoxy and lower alkoxy(lower)alkylthio,

imidazothiadiazolyl substituted with phenyl having lower alkoxy(lower)alkoxy,

phenyl subsutituted with piperazinyl having phenyl substituted with morpholino having lower alkyl,

isoxazolyl substituted with phenyl having lower alkoxy(lower)alkoxy,

isoxazolyl substituted with phenyl having higher alkoxy substituted with morpholino having lower alkyl,

thiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl which has one or more suitable substituent(s) selected from the group consisting of lower alkyl, lower alkenyl, lower alkoxy(higher)alkoxy and phenyl,

thiadiazolyl substituted with phenyl having piperazinyl substituted with lower alkyl having cyclo(lower)alkyl,

thiadiazolyl substituted with phenyl having piperidyl substituted with one or more suitable substituent(s) selected from the group consisting of cyclo(lower)alkyloxy, lower alkoxy(lower)alkoxy and lower alkoxy(lower)alkoxy(lower)alkyl,

thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl and lower alkoxy,

thiadiazolyl substituted with pyridyl having piperazinyl substituted with cyclo(lower)alkyl having lower alkyl,

imidazothiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl,

imidazothiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl having lower alkyl, and

phenyl substituted with piperazinyl having cyclo(lower)alkyl substituted with one or more suitable substituent(s) selected from the group consisting of cyclo(lower)alkyl which may have lower alkoxy, lower alkyl, lower alkoxy and phenyl which may have lower alkoxy,

R 2 is hydrogen,

R 3 is lower alkyl which has two hydroxy,

R 4 is hydrogen or hydroxy;

R 5 is hydroxy or hydroxysulfonyloxy; and

R 6 is hydroxy.

5. The compound of the claim 4 , wherein

R 1 is benzoyl which has thiadiazolyl substituted with phenyl having piperazinyl substituted with cyclo(lower)alkyl which has lower alkyl,

benzoyl which has thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyloxy,

benzoyl which has phenyl substituted with piperazinyl having cyclo(lower)alkyl substituted with cyclo(lower)alkyl and lower alkoxy, or

benzoyl which has thiadiazolyl substituted with phenyl having piperidyl substituted with cyclo(lower)alkyl,

R 2 is hydrogen,

R 3 is lower alkyl which has two hydroxy,

R 4 is hydrogen or hydroxy;

R 5 is hydroxy or hydroxysulfonyloxy; and

R 6 is hydroxy.

6. The compound of claim 4 , wherein

R 1 is benzoyl which has thiadiazolyl substituted with phenyl having a suitable substituent selected from the group consisting of

(1) piperazinyl substituted with cyclo(lower)alkyl which has lower alkyl, and

(2) piperidyl substituted with cyclo(lower)alkyl and (lower)alkoxy,

R 2 is hydrogen,

R 3 is lower alkyl which has two hydroxyl,

R 4 is hydrogen,

R 5 is hydroxysulfonyloxy, and

R 6 is hydroxyl.

7. The compound of claim 6 , wherein

R 1 is 4-[5-[4-[cis-4-(4-methylcyclohexyl)-piperazin-1-yl]phenyl]-1,3,4-thiadiazol-2-yl]benzoyl,

R 2 is hydrogen,

R 3 is 2-hydroxy-1-(hydroxymethyl)ethyl,

R 4 is hydrogen,

R 5 is hydroxysulfonyloxy, and

R 6 hydroxyl.

8. The compound of claim 6 , wherein

R 1 is 4-[5-[4-(4-methoxy-4-cyclohexyl-piperidin-1-yl)-phenyl]-1,3,4-thiadiazol-2-yl]benzoyl,

R 2 is hydrogen,

R 3 is 2-hydroxy-1-(hydroxymethyl)ethyl,

R 4 is hydrogen,

R 5 is hydroxysulfonyloxy, and

R 6 is hydroxyl.

9. A process for preparing a polypeptide compound (I) of claim 1 , or a salt thereof,

which comprises,

i) reacting a compound (II) of the formula:

or a salt thereof, with a compound (III) of the formula:

R 3 ═O  (III)

or its reactive derivative or a salt thereof, to give a compound (Ia) of the formula:

or a salt thereof, or

ii) reacting a compound (Ia) of the formula:

or a salt thereof, with a compound (IV) of the formula:

 R a 2 —OH  (IV)

wherein R a 1 is acyl group,

or its reactive derivative at the carboxy group or a salt thereof, to give a compound (Ib) of the formula:

or a salt thereof, or

iii) subjecting a compound (Ib) of the formula:

or a salt thereof, to elimination reaction of the acyl group, to give a (Ia) of the formula:

or a salt thereof, or

iv) reacting a compound (Ic) of the formula:

or a salt thereof, with a compound (V) of the formula:

R a 2 —OH  (V)

wherein R a 1 is acyl group,

or its reactive derivative at the carboxy group or a salt thereof, to give a compound (Id) of the formula:

or a salt thereof.

10. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.

11. A method of treating an infectious disease caused by a fungus comprising administering to a human being or an animal subject in need thereof compound according to claim 1 for a time and under conditions to treat said disease.

12. The commercial package comprising the pharmaceutical composition of claim 10 and a written matter associated therewith, wherein the written matter states that the pharmaceutical composition can be used for treating an infectious disease caused by a fungus.

13. An article of manufacture, comprising packaging material and the compound (I) identified in claim 1 contained within said packaging material wherein said compound (I) is therapeutically effective for treating an infectious disease caused by a fungus, and wherein said packaging material comprises a label or a written material which indicates that said compound (I) can be used for treating an infectious disease caused by a fungus.

Assignments (2)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2002
From: TODA, AYAKO; MATSUYA, TAKAHIRO; MIZUNO, HIROAKI; MATSUDA, HIROSHI; MURANO, KENJI; BARRETT, DAVID; OGINO, TAKASHI; MATSUDA, KEIJI
To: FUJISAWA PHARMACEUTICAL CO., LTD.
Reel/Frame 013060/0415 →